

昭衍
JOINN

603127

北京昭衍新药研究中心股份有限公司
2023 年年度报告摘要

第一节 重要提示

<http://www.sse.com.cn>

10

1.6

第二节 公司基本情况

A			603127	
H			06127	

1.

CRO

20 70

CRO

I -IV

FDA

CRO	CRO		Frost&Sullivan	2021	CRO
710	2026	CRO	1,185	2021-2026	
10.8%					

2.

CRO	20		90	CRO	
		CRO	Frost&Sullivan	2017	2021
CRO	290		640	21.8%	
	2026	1,878	2021-2026	24.1%	

CRO					CRO
CRO	2021	CRO	640		CRO
CRO		313	327		

3

		2020	1	15		2020	1
2020	7	1					

40

CRO

1.

CRO

1

30

2

CRO

PCC

ADME PK Non-GLP

2.

I BE

/

/

/

ADC

PROTAC

3.

1.

GLP

GLP

GLP

GLP

GLP

GLP

BIOMERE

2019

FDA

30

2.

1

2

SOP

3
4

3.

GLP

SOP

SOP

4.

1.

2.

3.

4.

1.

2.

3.

4.

1.

CRO

CRO

CRO

CAR-T

2.


3.

CNS

I II

,

	1-3	4-6	7-9	10-12
	369,386,010.95	642,691,277.23	575,002,491.20	789,407,017.72
	187,759,654.85	-97,132,500.76	236,971,204.96	69,394,206.74
	184,748,130.28	-107,861,663.87	234,201,796.98	26,476,479.47
	-13,668,184.06	259,877,932.43	202,230,470.05	174,434,920.02



10

第三节 重要事项

1

	237,648.68	4.78%
39,699.26	63.04%	